We Continue To Have Office Visits And Provide Treatment For Our Cancer Patients During The COVID Emergency. Call 718-780-3022 For An Appointment.
Accurate diagnosis, consultation, and staging are critical to successful cancer treatment. In recent years, there have been significant advances in technology. These advances mean quick and often painless screening examinations and highly sophisticated diagnostic evaluations.
NewYork-Presbyterian Brooklyn Methodist Hospital's Pathology Department tests samples taken at the Hospital or in a physician's office for diagnosis. These tests may include:
- Screening specimens such as PSA (prostate specific antigen) blood samples or PAP smears.
- Biopsies taken during surgical or stereotactic procedures.
- Blood work related to ongoing radiation or chemotherapy treatments.
Pathologists at NYPBMH perform fine needle aspiration biopsy, which is a quick and nearly painless technique for diagnosis. Stereotactic breast biopsy is a non-surgical procedure done on an outpatient basis. It provides quick results and is available at the Hospital's Women's Diagnostic Center.
The NewYork-Presbyterian Brooklyn Methodist Hospital Radiology Department provides a full spectrum of the most advanced imaging technologies for diagnosis.
In addition, genetic testing may be useful to determine an individual's chances of developing cancer. Testing for BRCA1 and BRCA2 genes, which may be predictors of breast or ovarian cancer, is available through the NYPBMH cytogenetics program. The program also offers follow-up genetic counseling.
Patients already diagnosed with cancer may wish to have a consultation or "get a second opinion." Physicians affiliated with the Institute are available to consult with patients, evaluate previous test results, and/or recommend additional diagnostic procedures. If a diagnosis of cancer is confirmed, Institute physicians discuss treatment options with the patient. NewYork-Presbyterian Brooklyn Methodist Hospital offers a wide range of services and care for all types of cancer through our Institute for Cancer Care.